23 OCT 2025 · FINANCING
Angel and Angel+ financing supports the in vivo CAR-T pipeline
Byterna announced Angel and Angel+ financing involving SunNovo Pharma, FOF Capital, Efung Capital and other investors.
The financing announcements described support for the company’s circular mRNA and in vivo CAR-T development work.
Financing is reported as a corporate milestone and is not evidence of product safety or efficacy.